CDPPB is a drug used in scientific research which acts as a positive allosteric modulator (PAM) selective for the metabotropic glutamate receptor subtype mGluR5 CDPPB was shown to be the first systemically available mGlu5 PAM, thus allowing for behavioral assessment in antipsychotic models, including reversal of amphetamine-induced hyperlocomotion and reversal of deficits in prepulse inhibition, both of which have translational validity in patients with schizophrenia eliciting positive symptoms and cognitive deficits in sensorimotor gating, respectively. CDPPB was shown to be efficacious in both of these models at moderate subcutaneous (s.c.) doses between 10 and 30 mg/kg. Numerous in vivo studies using CDPPB have recently surfaced which continue to add evidence and support for the potential to treat CNS disorders associated with aberrant NMDA receptor function, including the cognitive impairments and negative symptoms of schizophrenia.